Patents Assigned to The University of Washington
-
Publication number: 20100160419Abstract: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.Type: ApplicationFiled: October 16, 2009Publication date: June 24, 2010Applicants: Vical Incorporated, The University of WashingtonInventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
-
Publication number: 20100160418Abstract: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.Type: ApplicationFiled: October 16, 2009Publication date: June 24, 2010Applicants: Vical Incorporated, The University of WashingtonInventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
-
Patent number: 7671185Abstract: Disclosed are nucleotide sequences encoding monomeric variants of DsRed fluorescent proteins and methods of use thereof.Type: GrantFiled: May 15, 2007Date of Patent: March 2, 2010Assignees: The University of Chicago, The University of WashingtonInventors: Benjamin S. Glick, Brooke Bevis, Daniel E. Strongin, David Baker, Michelle Scalley-Kim
-
Patent number: 7655467Abstract: The present invention provides systemic nucleic acid sequence delivery without conventional systemic administration aids (SAAs). In certain embodiments, vascular permeability agents (VPAs), such as VEGF, are used in conjunction with nucleic acid viral vectors, such as adeno-associated virus (AAV). The present invention also provides methods of treating disease by co-administration of nucleic cid sequences encoding Igf-1 and dystrophin or dystrophin-like proteins.Type: GrantFiled: November 15, 2004Date of Patent: February 2, 2010Assignee: The University of WashingtonInventors: Jeffrey S. Chamberlain, Paul Gregorevic, Michael J. Blankinship, James M. Allen
-
Patent number: 7638269Abstract: A cell-free method for translation and assembly of viral capsid and capsid intermediates is disclosed. Also disclosed are novel capsid assembly intermediates and novel host proteins which bind to such assembly intermediates. The invention also includes a screening method for compounds that alter viral capsid assembly, and a method of treating viral infection using compounds which inhibit the capsid assembly pathway.Type: GrantFiled: September 13, 2002Date of Patent: December 29, 2009Assignees: The Regents of the University of California, The University of WashingtonInventors: Jaisri R. Lingappa, Kevin C. Klein, Vishwanath R. Lingappa
-
Publication number: 20090282948Abstract: Methods for forming nanostructures of various shapes are disclosed. Nanocubes, nanowires, nanopyramids and multiply twinned particles of silver may by formed by combining a solution of silver nitrate in ethylene glycol with a solution of poly(vinyl pyrrolidone) in ethylene glycol. Hollow nanostructures may be formed by reacting a solution of solid nanostructures comprising one of a first metal and a first metal alloy with a metal salt that can be reduced by the first metal or first metal alloy. Nanostructures comprising a core with at least one nanoshell may be formed by plating a nanostructure and reacting the plating with a metal salt.Type: ApplicationFiled: July 27, 2009Publication date: November 19, 2009Applicant: The University of WashingtonInventors: Younan Xia, Yugang Sun
-
Patent number: 7585349Abstract: Methods for forming nanostructures of various shapes are disclosed. Nanocubes, nanowires, nanopyramids and multiply twinned particles of silver may by formed by combining a solution of silver nitrate in ethylene glycol with a solution of poly(vinyl pyrrolidone) in ethylene glycol. Hollow nanostructures may be formed by reacting a solution of solid nanostructures comprising one of a first metal and a first metal alloy with a metal salt that can be reduced by the first metal or first metal alloy. Nanostructures comprising a core with at least one nanoshell may be formed by plating a nanostructure and reacting the plating with a metal salt.Type: GrantFiled: December 9, 2003Date of Patent: September 8, 2009Assignee: The University of WashingtonInventors: Younan Xia, Yugang Sun
-
Publication number: 20090208488Abstract: This invention provides antibodies that specifically bind to DCAL-2 and other DCAL-2 reagents that modulate dendritic cell function. Modulators of the receptor, including modulators that alter DCAL-2 associated signals to and from DCs, can be used to alter dendritic cell function and to enhance or inhibit immune responses to cancer antigens, autoantigens, or pathogens.Type: ApplicationFiled: May 22, 2007Publication date: August 20, 2009Applicant: The University of WashingtonInventors: Edward A. Clark, Chang Hung Chen, Helen Floyd
-
Patent number: 7575876Abstract: The present invention provides methods for diagnosing neurodegenerative disease, such as Alzheimer's Disease, Parkinson's Disease, and dementia with Lewy body disease by detecting a pattern of gene product expression in a cerebrospinal fluid sample and comparing the pattern of gene product expression from the sample to a library of gene product expression pattern known to be indicative of the presence or absence of a neurodegenerative disease. The methods also provide for monitoring neurodegenerative disease progression and assessing the effects of therapeutic treatment. Also provided are kits, systems and devices for practicing the subject methods.Type: GrantFiled: May 24, 2006Date of Patent: August 18, 2009Assignee: The University of WashingtonInventor: Jing Zhang
-
Publication number: 20090099035Abstract: Arrays of HLA Class I oligonucleotide probes on a solid support are provided, wherein the probes are sufficient to represent at least 80% of the known polymorphisms in exons 2 and 3 of the HLA Class I locus.Type: ApplicationFiled: November 25, 2008Publication date: April 16, 2009Applicants: Fred Hutchinson Cancer Research Center, The University of WashingtonInventors: Effie W. Petersdorf, Zhen Guo, John A. Hansen, Leroy Hood
-
Patent number: 7517851Abstract: Oligosaccharides specific for Chlamydia mediate attachment of the organism to host cells.Type: GrantFiled: March 16, 2006Date of Patent: April 14, 2009Assignee: The University of WashingtonInventors: Cho-chou Kuo, Albertina F. Swanson, Sen-Itiroh Hakomori, Noriko Takahashi
-
Publication number: 20080187912Abstract: Arrays of HLA Class I oligonucleotide probes on a solid support are provided, wherein the probes are sufficient to represent at least 80% of the known polymorphisms in exons 2 and 3 of the HLA Class I locus.Type: ApplicationFiled: September 7, 2006Publication date: August 7, 2008Applicants: Fred Hutchinson Cancer Research Center, The University of Washington Office of Technology TransferInventors: Effie W. Petersdorf, Zhen Guo, John A. Hansen, Leroy Hood
-
Patent number: 7402726Abstract: Methods and compositions for identifying an agent (e.g., a gene product or small molecule compound) that modulates a Parkinson's disease phenotype are provided. In practicing the subject methods, a non-mammalian animal model, such as Drosophila melanogaster, that includes a mutant parkin gene and at least one other mutant gene are evaluated for a Parkinson's disease phenotype. Also provided are kits, and systems for practicing the subject methods, as well as methods of use of agents identified in the screening method of the invention.Type: GrantFiled: February 8, 2005Date of Patent: July 22, 2008Assignee: The University of WashingtonInventors: Leo J. Pallanck, Jessica G. Zuniga, Alexander J. Whitworth
-
Patent number: 7372059Abstract: Various mechanisms are provided relating to plasma-based light source that may be used for lithography as well as other applications. For example, a device is disclosed for producing extreme ultraviolet (EUV) light based on a sheared plasma flow. The device can produce a plasma pinch that can last several orders of magnitude longer than what is typically sustained in a Z-pinch, thus enabling the device to provide more power output than what has been hitherto predicted in theory or attained in practice. Such power output may be used in a lithography system for manufacturing integrated circuits, enabling the use of EUV wavelengths on the order of about 13.5 nm. Lastly, the process of manufacturing such a plasma pinch is discussed, where the process includes providing a sheared flow of plasma in order to stabilize it for long periods of time.Type: GrantFiled: October 17, 2005Date of Patent: May 13, 2008Assignee: The University of WashingtonInventors: Uri Shumlak, Raymond Golingo, Brian A. Nelson
-
Publication number: 20080063561Abstract: An automated workstation or apparatus for disinfecting an object in a controlled environment is provided. A method for disinfecting an object in a controlled environment is provided.Type: ApplicationFiled: August 16, 2007Publication date: March 13, 2008Applicant: The University of WashingtonInventor: James Van Hooser
-
Patent number: 7341869Abstract: The present invention provides an isolated population of cells containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention also provides an isolated population of cells which further express a hexosamine synthetic pathway enzyme. The invention additionally provides vectors containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention further provides a method of treating or preventing diabetes by implanting into an individual cells coexpressing proinsulin containing a proinsulin cleavage site and a glucose-regulated protease capable of cleaving the proinsulin cleavage site to produce insulin.Type: GrantFiled: December 23, 2002Date of Patent: March 11, 2008Assignee: The University of WashingtonInventors: William R. A. Osborne, Nagarajan Ramesh
-
Publication number: 20080008706Abstract: The invention provides B7S1 nucleic acid, B7S1 polypeptides, and antibodies that bind B7S1 polypeptides. B7S1 sequences can be used, e.g., to screen for modulators of B7S1 activity. Modulators, e.g., antibodies or small molecules, can be used for the treatment of disease that involve an immune response.Type: ApplicationFiled: May 17, 2007Publication date: January 10, 2008Applicant: The University of WashingtonInventors: Chen Dong, Durbaka Pradas
-
Publication number: 20070270362Abstract: Methods and compositions are provided for treating inflammatory-related diseases and related disorders in a mammalian subject. The method provides administering to the mammalian subject one or more modulators of cyclin dependent kinase 4 (Cdk4) activity in an amount effective to reduce or eliminate the inflammatory-related disease or disorder or prevent its occurrence or recurrence. Methods are also provided for reducing or eliminating ligand-induced adhesion in a mammalian subject. The method provides administering to the subject one or more modulators of cyclin dependent kinase 4 (Cdk4) activity in an amount effective to reduce or eliminate ligand-induced adhesion.Type: ApplicationFiled: May 18, 2006Publication date: November 22, 2007Applicant: The University of WashingtonInventors: John M. Harlan, Lynn M. Schnapp, Barbara R. Schwartz, Li Liu, Elaine White Raines, Yoshiaki Tsubota
-
Patent number: 7250298Abstract: Disclosed are sequences encoding monomeric variants of DsRed fluorescent proteins and methods of use.Type: GrantFiled: April 7, 2005Date of Patent: July 31, 2007Assignees: The University of Chicago, The University of WashingtonInventors: Benjamin S. Glick, Brooke Bevis, Daniel E. Strongin, David Baker, Michelle Scalley-Kim
-
Publication number: 20060171929Abstract: This invention provides antibodies that specifically bind to DCAL-2 and other DCAL-2 reagents that modulate dendritic cell function. Modulators of the receptor, including modulators that alter DCAL-2 associated signals to and from DCs, can be used to alter dendritic cell function and to enhance or inhibit immune responses to cancer antigens, autoantigens, or pathogens.Type: ApplicationFiled: January 31, 2005Publication date: August 3, 2006Applicant: The University of WashingtonInventors: Edward Clark, Chang Hung Chen, Helen Floyd